Heuron Announces Commercialization of Complete AI-Based Stroke CT Analysis Series

May. 2025

– Full AI solution lineup covers NCCT, CTA, and CTP with automated AI analysis

– Accessible to healthcare institutions of all sizes, enabling broader clinical adoption

 

 


 

May 2025 – May 2025 – uron Co., Ltd., a medical AI company specializing in neurological disorders, has announced the successful commercialization of a complete series of AI solutions for stroke diagnosis. With the rollout of Heuron StroCare Suite™, Heuron CTA, and Heuron CTP, the company now offers a fully integrated AI-powered system that supports every major CT modality used in stroke assessment.


Stroke is a medical emergency in which early intervention during the "golden hour" is critical. Rapid and accurate diagnosis, effective triage, and timely transfer to appropriate treatment centers can significantly improve patient outcomes. Standard stroke imaging typically begins with a non-contrast CT (NCCT), followed by CT angiography (CTA) and CT perfusion (CTP) as needed. Since each scan serves a different purpose, comprehensive and prompt interpretation is vital to guide optimal treatment decisions.


Heuron StroCare Suite™ analyzes NCCT scans in under three minutes, automatically identifying intracerebral hemorrhages, detecting large vessel occlusions, and calculating ASPECTS scores. As the initial diagnostic step, this tool provides essential insights for early clinical decision-making. In 2024, it was designated as an “Innovative Medical Technology” by Korea’s Ministry of Health and Welfare in recognition of its clinical and technological value.


Heuron CTA, recently certified as a Class III medical device by the Ministry of Food and Drug Safety, processes CT angiography images to detect large vessel occlusions. It quantifies vessel density across brain hemispheres and presents the results using intuitive visualizations to quickly highlight occlusion sites. The tool also generates detailed 2D and 3D vascular maps to aid procedural planning and decision-making.


Heuron CTP analyzes perfusion CT scans by automatically calculating five key hemodynamic parameters—Tmax, CBF, CBV, MTT, and TTP—and presents them in color-coded maps to enhance visibility and interpretation of ischemic regions.

Together, these three solutions form a cohesive diagnostic series, enabling AI-powered support across the full CT-based stroke evaluation pathway. From the moment a suspected stroke patient enters the emergency room, clinicians can rely on AI to detect hemorrhages, assess large vessel occlusions, and quantify perfusion deficits—improving diagnostic speed, accuracy, and consistency.


Because the solutions are based on CT rather than MRI, they are more widely accessible across various levels of care. From primary care clinics to regional emergency centers and comprehensive stroke units, Heuron’s technology enables meaningful clinical application regardless of facility size or infrastructure.


“Our three AI solutions represent more than diagnostic tools—they define a new standard for stroke care,” said Donghoon Shin, CEO of Heuron. “AI is not about replacing medical judgment; it’s about empowering healthcare teams to make faster, more accurate decisions. With this complete series, we’re committed to expanding our global footprint and supporting more providers and patients worldwide.”

TOP